Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
NV

NASDAQ · NVACW

NorthView Acquisition Corporation

Financial Services · Shell Companies

$0.11

Down-$0.01 (-8.33%)

Updated Aug 23, 2026, 10:39 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.2M
P/E ratio
-0.14
Dividend yield
0.00%
52-week range
— – —
Volume
145.1K
Avg. volume
68.74K

Price performance

NVACW price history

1M range · 0 trading sessions · Daily adjusted prices

NVACW does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest NVACW news

The latest Smart Investors Daily articles mentioning NVACW.

Stock researchCompany · Overview

NVACW research

Overview

Company profile and research snapshot.

Company profile

PROFUSA INC WTS

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 27, 2026

Profusa Signs Term Sheet for Diagnostics Acquisition and Announces Leadership Changes

Profusa (NASDAQ:PFSA) has signed a non-binding term sheet to acquire a commercial-stage diagnostics company with estimated 2025 net revenue of approximately $111 million, while also reshaping its executive leadership as it pivots toward a diagnostics-focused business model. Key Investor TakeawaysProfusa (NASDAQ:PFSA) signed a non-binding term sheet to acquire a commercial-stage diagnostics company.

Yahoo · Jul 27, 2026

Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company

BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company (the "Dx Company"). Following the contemplated transaction, the combined company is expected to operate as a public diagnostics company with national CLIA-certified laboratories, recurring revenues fro

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By